IKENA ONCOLOGY
Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs.
IKENA ONCOLOGY
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.ikenaoncology.com
Total Employee:
11+
Status:
Active
Contact:
1-857-273-8343
Email Addresses:
[email protected]
Total Funding:
169 M USD
Technology used in webpage:
SPF Wordpress Plugins Nginx Microsoft Exchange Online Office 365 Mail GoDaddy DNS Mimecast
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Bristol Myers Squibb
Bristol Myers Squibb investment in Series B - Ikena Oncology
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series B - Ikena Oncology
Invus
Invus investment in Series B - Ikena Oncology
Farallon Capital Management
Farallon Capital Management investment in Series B - Ikena Oncology
Surveyor Capital
Surveyor Capital investment in Series B - Ikena Oncology
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - Ikena Oncology
OrbiMed
OrbiMed investment in Series B - Ikena Oncology
HealthCor Partners
HealthCor Partners investment in Series B - Ikena Oncology
Logos Capital
Logos Capital investment in Series B - Ikena Oncology
BVF Partners
BVF Partners investment in Series B - Ikena Oncology
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-13 | Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development |
Official Site Inspections
http://www.ikenaoncology.com Semrush global rank: 352.8 K Semrush visits lastest month: 167.49 K
- Host name: 66-135-14-109.constant.com
- IP address: 66.135.14.109
- Location: Salt Lake City United States
- Latitude: 40.6487
- Longitude: -111.9682
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84129
More informations about "Ikena Oncology"
Ikena Oncology | Ikena Oncology Outlines Key Priorities and …
Jan 18, 2024 This includes a workforce reduction of approximately 35%, to be implemented over the course of the first quarter of 2024 With approximately $175 million in cash and cash …See details»
Ikena Oncology Outlines Key Priorities and Provides Corporate
Jan 18, 2024 --Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, today provided an organizational update outlining key …See details»
Ikena Oncology Outlines Key Priorities and Provides
Jan 18, 2024 With approximately $175 million in cash and cash equivalents as of December 31, 2023 (unaudited), and as a result of the organization changes the Company’s runway is …See details»
About Us | Ikena Oncology
About Us At Ikena®, we strive to understand what drives every patient’s cancer. Each member of our team is committed to this goal and offers their unique se ...See details»
Ikena Oncology - 2025 Company Profile & Team - Tracxn
Jul 16, 2025 Ikena Oncology - Developer of biomarker-based therapies for treating cancer. Public Company. Raised a total funding of $168M over 3 rounds from 12 investors.See details»
Ikena Oncology | Inmagene Biopharmaceuticals Announces …
1 day ago Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 MillionSee details»
Ikena Oncology and Inmagene Biopharmaceuticals …
To learn more, visit www.ikenaoncology.com. About IMG-007 IMG-007 is a humanized anti-OX40 IgG1 mAb, with a silenced ADCC function and an …See details»
Ikena Oncology and Inmagene Biopharmaceuticals Announce …
2 days ago BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”) today …See details»
Ikena Oncology | Ikena Oncology Announces Stockholder …
BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) today announced the results of the annual meeting of its …See details»
Pipeline | Ikena Oncology
Our Pipeline At Ikena®, we are advancing a portfolio of targeted oncology therapies intended to enable a tumor directed approach for every patient. Our …See details»
Ikena Oncology and Inmagene Biopharmaceuticals Announce …
To learn more, visit www.ikenaoncology.com. About IMG-007 IMG-007 is a humanized, subcutaneously administered, non-depleting IgG1 monoclonal antibody targeting OX40. It …See details»
Ikena Oncology Outlines Key Priorities and Provides ... - BioSpace
Jan 18, 2024 Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, provided an organizational update outlining key objectives toward …See details»
Ikena Oncology Announces 1-for-12 Reverse Stock Split and
Jul 15, 2025 Ikena announces a merger with Inmagene and a 1-for-12 reverse stock split, trading under ticker "IMA" after completion.See details»
Contact - Ikena Oncology
Contact Us To learn more about our pipeline or to submit a general inquiry, please use the form below. Ikena Oncology® 645 Summer StreetSuite 101Boston, MA ...See details»
Ikena Oncology Announces Stockholder Approval of Merger
Jul 15, 2025 Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals July 15, 2025 16:15 ET | Source: Ikena Oncology, Inc.See details»
Ikena Oncology | Ikena Oncology Reports Fourth Quarter and Full …
The Company also provided an update across the organization and pipeline. “We are diligently executing on our clinical programs while we strive to broaden the type and number of patients …See details»
Ikena Oncology Outlines Key Priorities and Provides Corporate …
Jan 18, 2024 IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window …See details»
Careers - Ikena Oncology
All Ikenians are committed to being culture champions, nurturing relationships across the organization, and driving ourselves and our colleagues to significantly impact the patients we …See details»
Ikena Oncology | Ikena Oncology and Inmagene …
3 days ago To learn more, visit www.ikenaoncology.com. About IMG-007 IMG-007 is a humanized, subcutaneously administered, non-depleting IgG1 monoclonal antibody targeting …See details»
Investor FAQs - Ikena Oncology
The Investor Relations website contains information about Ikena Oncology's business for stockholders, potential investors, and financial analysts.See details»